Interaction Between theμ-Opioid Receptor Gene and the Number of Heavy-Drinking Peers on Alcohol Use

IntroductionAlcohol consumption represents a significant factor for mortality in the world: 6.3% in men and 1.1% in women. Alcohol use disorder is also very common: 5.4% in men and 1.5% in women. Despite its high frequency and the seriousness of this disorder, only 8% of all alcohol-dependents are ever treated. One potentially interesting treatment option is oriented toward reducing alcohol intake.AimsTo describe one case who has improved his alcohol consumption after starting treatment with nalmefene, an opioid receptor antagonist related to naltrexone.MethodsA 35-year-old male with alcohol use disorder since 2001 came to our consult in November 2015. He was in trouble with his family and he had a liver failure. We offer a new treatment option with nalmefene 18 mg to reduce alcohol consumption.ResultsBefore to start nalmefene he drank 21 drinks/week. Six-month later, he decreased alcohol intake until 5 drinks/week with better family relationship and liver function. After starting nalmefene he complained of nausea, so we recommend to take the middle of the pill for next 7 days. After this time he returned to take one pill with good tolerance and no more side effects or withdrawal syndrome.ConclusionsNalmefene appears to be effective and safe in reducing heavy drinking and in preventing alcohol withdrawal syndrome due to its opioid receptor antagonism. This case suggests nalmefene is a potential option to help patients, who do not want or cannot get the abstinence, in reducing their alcohol consumption.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Variation in Mu-Opioid Receptor Gene (OPRM1) as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort

Journal of Alcoholism and Drug Dependence ◽

10.4172/2329-6488.1000101 ◽

2013 ◽

Vol 01 (01) ◽

Cited By ~ 1

Author(s):

Andrew CH Chen Jon Morgenstern ◽

Christine M Davis Alexis N Kuerbis

Keyword(s):

Opioid Receptor ◽

Receptor Gene ◽

Heavy Drinking ◽

Mu Opioid Receptor ◽

Mu Opioid ◽

High Functioning ◽

Naltrexone Treatment

Download Full-text

Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial

Alcohol and Alcoholism ◽

10.1093/alcalc/agz046 ◽

2019 ◽

Vol 54 (5) ◽

pp. 559-565

Author(s):

Daniel J O Roche ◽

Constantine J Trela ◽

Maria Argos ◽

Farzana Jasmine ◽

Muhammad G Kibriya ◽

...

Keyword(s):

Smoking Cessation ◽

Weight Gain ◽

Opioid Receptor ◽

Receptor Gene ◽

Drinking Behavior ◽

Heavy Drinking ◽

Primary Objective ◽

Double Blind ◽

Quit Rate ◽

Relationship Of

Abstract Aims The present study examined how variation in mu- (OPRM1), kappa- (OPRK), and delta- (OPRD) opioid receptor genes may influence the efficacy of naltrexone in the context of a smoking cessation trial. Methods The study’s primary objective was to examine the association of the Asn40Asp OPRM1 single nucleotide polymorphism (SNP) with naltrexone’s effects on smoking quit rate, weight gain, and heavy drinking behavior during a double-blind, randomized clinical trial in 280 adult DSM-IV nicotine-dependent participants. The secondary goal of the study was to examine the relationship of 20 additional SNPs of OPRM1, OPRK, and OPRD with the aforementioned outcomes. Results Results indicated a null association between any opioid-receptor gene SNP and naltrexone’s effects on smoking quit rate, weight gain, and heavy drinking behavior in this sample of nicotine dependent participants. Conclusions In sum, these results do not suggest that genetic variation in opioid-receptors is related to treatment responses to naltrexone in a smoking cessation trial.

Download Full-text

The Moderating Effect of Alcohol-Specific Parental Rule-Setting on the Relation between the Dopamine D2 Receptor Gene (DRD2), the Mu-Opioid Receptor Gene (OPRM1) and Alcohol Use in Young Adolescents

Alcohol and Alcoholism ◽

10.1093/alcalc/ags075 ◽

2012 ◽

Vol 47 (6) ◽

pp. 663-670 ◽

Cited By ~ 14

Author(s):

Sara Pieters ◽

Carmen S. Van Der Zwaluw ◽

Haske Van Der Vorst ◽

Reinout W. Wiers ◽

Hubert Smeets ◽

...

Keyword(s):

Alcohol Use ◽

Opioid Receptor ◽

Dopamine D2 Receptor ◽

Receptor Gene ◽

D2 Receptor ◽

Mu Opioid Receptor ◽

Moderating Effect ◽

Young Adolescents ◽

Mu Opioid ◽

Rule Setting

Download Full-text

Systematic review and meta‐analysis of the moderating effect of rs1799971 in OPRM1 , the mu‐opioid receptor gene, on response to naltrexone treatment of alcohol use disorder

Addiction ◽

10.1111/add.14975 ◽

2020 ◽

Vol 115 (8) ◽

pp. 1426-1437 ◽

Cited By ~ 7

Author(s):

Emily E. Hartwell ◽

Richard Feinn ◽

Paige E. Morris ◽

Joel Gelernter ◽

John Krystal ◽

...

Keyword(s):

Systematic Review ◽

Alcohol Use ◽

Opioid Receptor ◽

Alcohol Use Disorder ◽

Meta Analysis ◽

Receptor Gene ◽

Mu Opioid Receptor ◽

Moderating Effect ◽

Mu Opioid ◽

Naltrexone Treatment

Download Full-text

Association of opioid receptor gene polymorphisms with drinking severity and impulsivity related to alcohol use disorder in a Korean population

CNS Neuroscience & Therapeutics ◽

10.1111/cns.13138 ◽

2019 ◽

Vol 26 (1) ◽

pp. 30-38 ◽

Cited By ~ 1

Author(s):

Chun Il Park ◽

Syung Shick Hwang ◽

Hae Won Kim ◽

Jee In Kang ◽

Sang Hak Lee ◽

...

Keyword(s):

Alcohol Use ◽

Opioid Receptor ◽

Gene Polymorphisms ◽

Alcohol Use Disorder ◽

Receptor Gene ◽

Korean Population ◽

Receptor Gene Polymorphisms

Download Full-text

Faculty Opinions recommendation of A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119600.577817 ◽

2008 ◽

Author(s):

George Breese ◽

Mary Katherine Kelm

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Heavy Drinking ◽

Ethanol Consumption ◽

Delta Opioid Receptor ◽

Opioid Receptor Antagonist

Download Full-text

Variation of the human mu-opioid receptor (OPRM1) gene predicts vulnerability to frustration

Scientific Reports ◽

10.1038/s41598-020-78783-4 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Alan M. Daniel ◽

Brenda G. Rushing ◽

Karla Y. Tapia Menchaca

Keyword(s):

Individual Differences ◽

Animal Models ◽

Opioid Receptor ◽

Receptor Gene ◽

Emotional Reaction ◽

Mu Opioid Receptor ◽

Reward Processing ◽

Physical Pain ◽

Mu Opioid ◽

Allelic Differences

AbstractUnderstanding the emotional reaction to loss, or frustration, is a critical problem for the field of mental health. Animal models of loss have pointed to the opioid system as a nexus of frustration, physical pain, and substance abuse. However, few attempts have been made to connect the results of animal models of loss to human behavior. Allelic differences in the human mu opioid receptor gene, notably the A118G single nucleotide polymorphism, have been linked to individual differences in pain sensitivity, depressive symptoms, and reward processing. The present study explored the relationship between A118G and behavior in two frustrating tasks in humans. Results showed that carriers of the mutant G-allele were slower to recover behavior following a reward downshift and abandoned a frustrating task earlier than those without the mutation. Additionally, G-carriers were more sensitive to physical pain. These results highlight the overlap between frustration and pain, and suggest that genetic variation in opioid tone may contribute to individual differences in vulnerability and resilience following emotional disturbances.

Download Full-text

Alcohol and Tobacco Use in a Tuberculosis Treatment Cohort during South Africa’s COVID-19 Sales Bans: A Case Series

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18105449 ◽

2021 ◽

Vol 18 (10) ◽

pp. 5449

Author(s):

Bronwyn Myers ◽

Tara Carney ◽

Jennifer Rooney ◽

Samantha Malatesta ◽

Laura F. White ◽

...

Keyword(s):

Alcohol Use ◽

Tobacco Use ◽

Heavy Drinking ◽

Case Series ◽

Tobacco Consumption ◽

Tuberculosis Treatment ◽

Behavior Change Interventions ◽

Patterns Of Drinking ◽

Tobacco Ban ◽

Drinking Occasion

Background: South Africa temporarily banned alcohol and tobacco sales for about 20 weeks during the COVID-19 lockdown. We described changes in alcohol and tobacco consumption after implementation of these restrictions among a small number of participants in a tuberculosis treatment cohort. Method: The timeline follow-back procedure and Fägerstrom test for nicotine dependence was used to collect monthly alcohol and tobacco use information. We report changes in heavy drinking days (HDD), average amount of absolute alcohol (AA) consumed per drinking day, and cigarettes smoked daily during the alcohol and tobacco ban compared to use prior to the ban. Results: Of the 61 participants for whom we have pre-ban and within-ban alcohol use information, 17 (27.9%) reported within-ban alcohol use. On average, participants reported one less HDD per fortnight (interquartile range (IQR): −4, 1), but their amount of AA consumed increased by 37.4 g per drinking occasion (IQR: −65.9 g, 71.0 g). Of 53 participants who reported pre-ban tobacco use, 17 (32.1%) stopped smoking during the ban. The number of participants smoking >10 cigarettes per day decreased from 8 to 1. Conclusions: From these observations, we hypothesize that policies restricting alcohol and tobacco availability seem to enable some individuals to reduce their consumption. However, these appear to have little effect on the volume of AA consumed among individuals with more harmful patterns of drinking in the absence of additional behavior change interventions.

Download Full-text